טוען...
Predictors of duration of abiraterone acetate in men with castration resistant prostate cancer
BACKGROUND: Androgen receptor signaling remains important in castration resistant prostate cancer (CRPC) as demonstrated by the efficacy of abiraterone acetate (henceforth abiraterone) in phase III trials. Given that heterogeneous patient responses are observed, we sought to determine clinical facto...
שמור ב:
| הוצא לאור ב: | Prostate Cancer Prostatic Dis |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6034654/ https://ncbi.nlm.nih.gov/pubmed/27502737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2016.31 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|